Perhexiline    (DrugBank: Perhexiline)

2 diseases
IDDisease name (Link within this page)Number of trials
58Hypertrophic cardiomyopathy5
272Fibrodysplasia ossificans progressiva1

58. Hypertrophic cardiomyopathy    [ 92 clinical trials,   126 drugs,   (DrugBank: 35 drugs),   40 drug target genes,   141 drug target pathways]
Searched query = "Hypertrophic cardiomyopathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
5 / 92 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04426578
(ClinicalTrials.gov)
August 1, 202014/5/2020Role of Perhexiline in Hypertrophic CardiomyopathyRandomised Controlled Trial of pErhexiline on regreSsion Of Left Ventricular hypErtrophy (LVH) in Patients With Symptomatic Hypertrophic CardioMyopathy (RESOLVE-HCM)Hypertrophic CardiomyopathyDrug: Perhexiline;Other: PlaceboFlinders UniversityNULLNot yet recruiting18 YearsN/AAll60Phase 2NULL
2NCT02862600
(ClinicalTrials.gov)
August 1, 20168/8/2016Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart FailureA Phase 2, Multi-Center, Open-Label, Ascending Dose Study on the Efficacy, Safety and Tolerability of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure With Preserved Left Ventricular FunctionCardiomyopathy, Hypertrophic;Cardiomyopathy, Hypertrophic, FamilialDrug: Perhexiline;Device: Use of bioanalytical assay to monitor plasma levels of perhexilineHeart Metabolics LimitedNULLTerminated18 YearsN/AAll35Phase 2United States
3NCT02431221
(ClinicalTrials.gov)
July 22, 201527/4/2015Efficacy, Safety, and Tolerability of Perhexiline in Subjects With Hypertrophic Cardiomyopathy and Heart FailureA Study on the Efficacy, Safety, and Tolerability of Perhexiline Maleate in Subjects With Hypertrophic Cardiomyopathy and Moderate-To-Severe Heart FailureHypertrophic CardiomyopathyDrug: Perhexiline;Drug: PlaceboHeart Metabolics LimitedNULLWithdrawn18 YearsN/AAll0Phase 3NULL
4NCT00500552
(ClinicalTrials.gov)
December 200610/7/2007Perhexiline Therapy in Patients With Hypertrophic CardiomyopathyMetabolic Alteration With Perhexiline Therapy in Patients With Hypertrophic Cardiomyopathy (METAL-HCM Study)Hypertrophic CardiomyopathyDrug: Perhexiline/PlaceboUniversity Hospital BirminghamBritish Heart Foundation;University College London Hospitals;University of OxfordCompleted18 Years80 YearsBoth44Phase 2United Kingdom
5EUCTR2005-000755-15-GB
(EUCTR)
25/10/200527/05/2005Perhexiline therapy in patients with Hypertrophic CardiomyopathyPerhexiline therapy in patients with Hypertrophic Cardiomyopathy Hypertrophic CardiomyopathyProduct Name: Pexsig
INN or Proposed INN: Perxexiline
University Hospital of Birmingham Foundation TrustNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
50United Kingdom

272. Fibrodysplasia ossificans progressiva    [ 23 clinical trials,   21 drugs,   (DrugBank: 4 drugs),   10 drug target genes,   87 drug target pathways]
Searched query = "Fibrodysplasia ossificans progressiva", "FOP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 23 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-UMIN000019348
2010/07/0114/10/2015Approved calcium channel blocker in the treatment of fibrodysplasia ossificans progressiva (FOP) fibrodysplasia ossificans progressivaoral administration of perhexiline maleate for one yearNagoya University Graduate School of MedicineNULLComplete: follow-up complete15years-old65years-oldMale and Female5Phase 1;Phase 2Japan